Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index; 70 of the 133 sources its claims cite were checked for support.

Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms

Open access
Abie Horowitz, Mark, Framer, Adele, Strang, John, Taylor, David · 2025 · Therapeutic Advances in Psychopharmacology

Abstract

Formal guidelines recommend that opioids should be stopped when risks outweigh benefits. These guidelines generally recommend gradual dose tapering at a rate tolerable to the patient. We examined the pharmacodynamic properties of opioids to derive pharmacologically rational principles for tapering. As dictated by the law of mass action, the relationship between dose of opioid and effect on its principal target, the mu-opioid receptor, is hyperbolic, with diminishing incremental effects for increasing doses. This suggests that in order to mitigate withdrawal symptoms, opioid doses should be tapered according to a corresponding hyperbolic pattern, with dose reductions becoming increasingly small as total dose reduces. This can be approximated by proportional decreases (e.g. 1%–10% reduction of the most recent dose every 1–2 weeks). Dose reductions should be titrated to withdrawal symptoms throughout the process, and final doses before complete cessation will need to be very small (such as 0.1 mg of buprenorphine or 1 mg of methadone, or less).

Overview

CoChat Summary

## TL;DR

This paper argues that opioid tapers should generally follow a hyperbolic pattern, not a linear one, because the dose–mu-opioid receptor relationship is hyperbolic and linear tapers can cause disproportionately large receptor changes at low doses. The authors propose proportional reductions of the most recent dose, with very small final doses and adjustments based on withdrawal symptoms.

## Key findings

  • The paper reports that opioid effects on the mu-opioid receptor (MOR) are hyperbolic, with diminishing incremental effects at higher doses, so tapering should also be hyperbolic to produce more even reductions in receptor occupancy.
  • In buprenorphine data from Greenwald et al. measured 4 h after 12 days of maintenance treatment at 1–32 mg, reducing by 4 mg from 16 mg caused a 5.2 percentage-point drop in MOR activity, whereas reducing by 4 mg from 4 mg to 0 mg caused a 53.9 percentage-point drop.
  • The abstract recommends proportional dose reductions of about 1%–10% of the most recent dose every 1–2 weeks, with final doses before cessation possibly as low as 0.1 mg of buprenorphine or 1 mg of methadone, or less.
  • Cited observational evidence suggests slower tapers do better: tapers of 12–52 weeks were 3.6 times more likely to succeed and tapers >52 weeks were 6.7 times more likely to succeed than tapers <12 weeks; another study found <5%/week doubling the chance of stopping opioids versus 5%–10%/week, and <5 mg methadone/week gave a 5-fold increased chance of a positive outcome versus >10 mg/week.

## Methods

  • This is a conceptual/narrative review that uses pharmacodynamic principles, especially the law of mass action, to derive tapering schedules.
  • The authors searched published studies via Google Scholar on MOR occupancy measured by PET in clinical subjects and on relationships between occupancy and clinical effects, including withdrawal; they state there was a single buprenorphine occupancy study used for dose-reduction calculations.
  • They also briefly reviewed evidence on taper duration, adjunctive medications, and nonpharmacological aspects of stopping opioids.

## Limitations

  • The paper states that individual pharmacodynamic and pharmacokinetic differences mean average-based taper regimens should be used cautiously, and withdrawal symptoms should guide the pace for each patient.
  • It states that much of the tapering logic is based on approximations: receptor-occupancy data were measured 4 h post-dose rather than at peak or trough, and for most opioids there are no primary MOR-occupancy data, so regimens are extrapolated from buprenorphine or dose conversions.
  • The text makes evident that the paper is not an empirical trial of the proposed tapering schedules, but a theory- and evidence-informed proposal; the authors explicitly call for randomized controlled trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253251371504

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. (a) Linear dose reductions recommended in a fast taper by the Centres for Disease Control (CDC). 1 The graph shows cumulative dose reductions over time expressed as a percentage of the starting dose. (b) Stepped linear dose reductions recommended by the Royal College of General Practitioners, which approximates an exponentially decreasing pattern of dose reduction. 10 The graph shows cumulative dose reductions over time expressed as a percentage of the starting dose.
Figure 1. (a) Linear dose reductions recommended in a fast taper by the Centres for Disease Control (CDC). 1 The graph shows cumulative dose reductions over time expressed as a percentage of the starting dose. (b) Stepped linear dose reductions recommended by the Royal College of General Practitioners, which approximates an exponentially decreasing pattern of dose reduction. 10 The graph shows cumulative dose reductions over time expressed as a percentage of the starting dose.CC BY-NC · PubMed Central
Figure 2. (a) Linear reductions of dose produce increasingly large reductions in effect on the MOR. (b) Hyperbolically reducing doses are required to produce equal-sized reductions in effect on the MOR (in this case 20 percentage points). Note how small final reductions before zero will be required to be to prevent a greater decrease in effect than has been tolerable for previous steps. MOR, mu-opioid receptor.
Figure 2. (a) Linear reductions of dose produce increasingly large reductions in effect on the MOR. (b) Hyperbolically reducing doses are required to produce equal-sized reductions in effect on the MOR (in this case 20 percentage points). Note how small final reductions before zero will be required to be to prevent a greater decrease in effect than has been tolerable for previous steps. MOR, mu-opioid receptor.CC BY-NC · PubMed Central
Figure 3. Average dose of methadone in groups assigned to different tapering protocols of methadone. There were small deviations from protocol for the gradual withdrawal (GW) group (3% original dose/week). There were much greater deviations from protocol for the rapid withdrawal (RW) group (10% of original dose/week) that increased as total doses became smaller. This is consistent with the notion that fixed reductions of dose at lower doses have increasingly larger aversive withdrawal effects because they transduce increasingly large reductions in MOR occupancy. Source: Figure adapted from Senay et al. 35 MOR, mu-opioid receptor.
Figure 3. Average dose of methadone in groups assigned to different tapering protocols of methadone. There were small deviations from protocol for the gradual withdrawal (GW) group (3% original dose/week). There were much greater deviations from protocol for the rapid withdrawal (RW) group (10% of original dose/week) that increased as total doses became smaller. This is consistent with the notion that fixed reductions of dose at lower doses have increasingly larger aversive withdrawal effects because they transduce increasingly large reductions in MOR occupancy. Source: Figure adapted from Senay et al. 35 MOR, mu-opioid receptor.CC BY-NC · PubMed Central
Figure 4. (a) The relationship between dose of methadone in mice and its anti-nociceptive effect is hyperbolic, derived from data in Doi et al. 41 (b) The relationship between in vitro concentration of methadone and proportion of MOR binding (measured by displacement of radio-labelled DAMGO) in membranes of mouse is hyperbolic, derived from data in Doi et al. 41 (c) The relationship between oral dose of methadone and reduction in pupil size compared with placebo in humans, derived from data in Eissenberg et al. 40 (d) The relationship between oral dose of methadone and reported drug effect (‘Do you feel any drug effect?’) in humans, derived from data in Eissenberg et al. 40 MOR, mu-opioid receptor.
Figure 4. (a) The relationship between dose of methadone in mice and its anti-nociceptive effect is hyperbolic, derived from data in Doi et al. 41 (b) The relationship between in vitro concentration of methadone and proportion of MOR binding (measured by displacement of radio-labelled DAMGO) in membranes of mouse is hyperbolic, derived from data in Doi et al. 41 (c) The relationship between oral dose of methadone and reduction in pupil size compared with placebo in humans, derived from data in Eissenberg et al. 40 (d) The relationship between oral dose of methadone and reported drug effect (‘Do you feel any drug effect?’) in humans, derived from data in Eissenberg et al. 40 MOR, mu-opioid receptor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

47 Valid · 14 Not valid · 42 Not checked · 36 Own results and interpretations

72 more claims · 35 with their cited sources checked

Create a free account to see all 139 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 29

Create a free account to see these claims.

Citations

Cites

Show all 53 references

Research works printed but not linked: 8

  1. Dowell D. HHS Guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Washington, DC: The US Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. 2019, pp. 1–6.
  2. National Institute for Health and Care Excellence. Opioid dependence. London, UK: National Institute for Health and Care Excellence, 2019.
  3. Lintzeris N, Clark N, Winstock A, et al. National clinical guidelines and procedures for the use of buprenorphine in the maintenance treatment of opioid dependence. Australian Government. 2006.
  4. Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry: 13th Edition. Hoboken, NJ: Wiley Blackwell, 2018.
  5. Horowitz MA Taylor D. Case-based learning: safe withdrawal and tapering of antidepressants [Internet]. The Pharmaceutical Journal https://pharmaceutical-journal.com/article/ld/case-based-learning-safe-withdrawal-and-tapering-of-antidepressants (2023 accessed 6 October 2023).
  6. Center for Substance Abuse Treatment. Protracted withdrawal. Substance Abuse Treatment Advisory 2010; 9(1): 1–8.
  7. JAMA Network Open. Data processing and patient eligibility indicator errors in study about dose tapering among patients prescribed long-term opioid therapy. JAMA Network Open. 2020; 3(8): e2018893–e2018893.
  8. Kumar R Viswanath O Saadabadi A. Buprenorphine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing https://www.ncbi.nlm.nih.gov/books/NBK459126/ (2024 accessed 9 Oct 2024).

Cited by

See all 1

Metadata

Authors
Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D.
Affiliations
  • Department of Research and Development, North East London Foundation Trust, Goodmayes Hospital, 157 Barley Ln, Goodmayes, Ilford IG3 8XJ, UK
  • Psychotropic Deprescribing Council, San Francisco, CA, USA
  • King's College London (GB)
Venue
Therapeutic Advances in Psychopharmacology
Published
2025-10
Volume
15
Pages
20451253251371504-20451253251371504
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4415732754
Cited by
0
References
53
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
opioid tapering, opioid withdrawal, dose tapering, mu-opioid receptor, pharmacodynamics, buprenorphine, methadone, opioid cessation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms. https://app.cochat.ai/papers/10.1177/20451253251371504
The paper
Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025). Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253251371504

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.